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Abstract(
(
Fewer'than'33%'of'those'testing'HIV-positive'in'sub-Saharan'Africa'are'continuously'retained'in'pre-
antiretroviral'therapy'(ART)'HIV'care'until'ART'initiation.'Existing'evidence'is'difficult'to'synthesize,'
however,'due'to'unclear'and'inconsistent'definitions'of'terms.'We'developed'practical,'standardized'
definitions'for'reporting'retention'for'the'three'stages'of'pre-ART'care:'Stage'1,'testing'HIV-positive'to'
initial'ART'eligibility'assessment;'Stage'2,'initial'assessment'to'ART'eligibility;'and'Stage'3,'ART'eligibility'
to'ART'initiation.'For'each'stage,'negative'outcomes'include'death,'loss,'or'not'being'retained.'Stage'1'
retention'is'defined'as'the'proportion'of'patients'who'complete'initial'ART'eligibility'assessment'within'
3'months'of'HIV'testing,'with'reporting'of'cohort'outcomes'at'3'and'12'months'after'HIV'testing.'
Patients'who'end'Stage'1'eligible'for'ART'move'directly'to'Stage'3.'Stage'2'retention'is'defined'as'the'
proportion'of'patients'who'either'complete'all'possible'ART'eligibility're-assessments'within'6'months'of'
the'site’s'standard'visit'schedule'or'had'an'assessment'within'1'year'of'the'time'reported'to'and'were'
not'ART'eligible'at'the'last'assessment.'Retention'should'be'reported'at'12-month'intervals.'Stage'3'
retention'is'defined'as'the'proportion'of'patients'eligible'for'ART'who'initiate'ART'(i.e.'ARVs'dispensed)'
within'3'months'of'determining'ART'eligibility,'with'reporting'at'3'months'after'eligibility'and'3'monthly'
intervals'thereafter.''If'pre-ART'retention'is'to'improve,'consistent'terminology'is'needed'for'collecting'
data,'measuring'and'reporting'outcomes,'and'comparing'results'across'programs'and'countries.'The'
definitions'we'propose'offer'a'strategy'for'improving'the'consistency'and'comparability'of'future'
reports.'
(
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Introduction(
(
Although'some'five'million'patients'are'currently'accessing'antiretroviral'treatment'(ART)'globally,1'late'
presentation'for'ART,'as'represented'by'persistently'low'CD4'counts'at'ART'initiation,'continues'to'be'
the'norm'in'many'parts'of'the'world.2-5'This'phenomenon'prevails'even'where'widespread'HIV'testing'is'
available,'due'in'part'to'failure'of'patients'who'are'not'yet'eligible'for'treatment'when'diagnosed6-10'to'
enroll'and'remain'in'pre-ART'medical'care'for'HIV/AIDS'and'failure'to'initiate'treatment'promptly'
among'those'who'are'already'ART'eligible'at'HIV'diagnosis.11'In'a'recent'systematic'review,'we'
estimated'that'fewer'than'a'third'of'patients'who'test'HIV-positive'in'sub-Saharan'Africa'remain'
continuously'in'pre-ART'care'until'ART'initiation.12''
'
While'the'systematic'review'made'clear'that'patient'attrition'from'pre-ART'medical'care'for'HIV/AIDS'
(pre-ART'care'for'short)'is'very'high,'the'literature'on'retention'in'pre-ART'care'was'difficult'to'
synthesize'due'to'unclear'and'widely'inconsistent'definitions'of'terms'and'time'intervals'for'reporting'
on'cohort'outcomes.'We'found'that'follow-up'intervals'to'determine'the'proportion'of'a'cohort'that'
had'achieved'a'specific'outcome,'such'as'some'measure'of'retention'in'pre-ART'care'prior'to'ART'
eligibility,'ranged'from'7'to'1826'days.'The'outcomes'reported'included'“enrolled'in'care,”'“linked'to'
care,”'“still'in'care'at'date'of'data'censoring,”'“repeat'CD4'count'one'year'after'initial'assessment,”'“less'
than'30'days'late'for'last'visit,”'and'others.'''
'
To'some'extent'this'lack'of'consistency'is'to'be'expected.'Even'more'than'the'period'after'ART'initiation,'
the'pre-ART'period'usually'requires'tracking'patients'across'multiple'sites'(e.g.'from'a'testing'site'to'a'
referral'site),'is'dependent'on'program-specific'schedules'for'repeated'visits,'lacks'clear'start'and'end'
points,'and'requires'a'long'duration'of'follow-up'before'patients'reach'outcomes'of'interest.'In'addition,'
the'data'needed'for'measuring'pre-ART'retention'are'often'not'routinely'captured'by'large-scale'HIV'
treatment'programs,'which'to'date'have'focused'their'efforts'on'patients'who'have'initiated'ART.'
'
Some'of'the'difficulty'in'interpreting'studies'of'pre-ART'care'arises'from'a'lack'of'consistent'methods'on'
the'part'of'researchers.'Our'review'called'for'proposals'for'clearly'defined'terminology,'definitions,'time'
intervals,'and'end'points'that'should'be'reported'when'describing'retention'in'pre-ART'care'for'a'
patient'cohort.'Here'we'examine'the'challenges'in'developing'clear'definitions,'propose'a'definition'for'
attrition'and'retention'in'each'stage'of'pre-ART'care,'and'discuss'the'data'required'for'accurately'
measuring'retention.'
'
Stages(of(pre9ART(care(
(
Most'pre-ART'care'programs'in'resource-constrained'countries'are'designed'to'have'patients'pass'
through'a'series'of'steps'between'testing'positive'for'HIV'and'initiating'ART.'The'content'of'pre-ART'
care'programs'varies'widely'by'country'and'service'provider,'ranging'from'simple'monitoring'of'ART'
eligibility'to'a'full'package'of'health'and'social'services''to,'more'rarely,'education'for'prevention'of'
transmission'to'others.13''For'purposes'of'consistent'measurement'in'cohorts'across'countries'and'
service'providers,'we'focus'on'ART'eligibility'monitoring'as'the'essential'component'of'pre-ART'care.''
Key'concepts'related'to'pre-ART'care'are'defined'in'Panel'1.'
'
As'in'our'previous'review,12'we'divide'pre-ART'care'into'three'discrete'stages'of'care.'These'stages'are'
defined'in'Figure'1'and'Panel'2.'(We'used'the'literature'and'field'experience'to'develop'practical,'
standardized,'and'quantifiable'definitions'for'reporting'retention'among'cohorts'of'patients'for'the'
three'stages'of'pre-ART'care.''In'Panel'3'and'below,'we'recommend'a'standard'definition'for'retention'
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in'each'stage'of'pre-ART.'To'improve'the'clarity'of'reported'estimates,'we'recommend'reporting'pre-
ART'retention'to'a'consistent'duration'of'follow'up'for'all'patients'in'the'cohort'and'avoiding'reporting'
to'a'date'of'censoring.'''
'
Panel(1(9(Definitions(of(key(concepts(in(pre9ART(care'
CONCEPT( DEFINITION(
Pre9ART(care' All'services'provided'to'patients'between'testing'positive'for'HIV'and'
dispensing'of'the'first'dose'of'ARVs.(
Enrollment(in(pre9ART(care' Active'(intentional)'registration'by'a'patient'in'any'form'of'pre-ART'care,'
regardless'of'whether'this'occurs'before'or'after'initial'ART'eligibility'
assessment.(
ART(eligibility(assessment' The'process'of'determining'if'a'patient'should'be'referred'to'or'continue'
in'pre-ART'care'or'should'initiate'ART,'typically'determined'through'a'CD4'
count'or'on'the'basis'of'WHO'stage.(
Retention' Active'engagement'in'pre-ART'care'as'required'by'the'specific'care'
program'over'time,'which'is'defined'for'each'stage'of'pre-ART'care'below(
Loss(to(care((or(attrition)' Discontinuation'of'active'engagement'in'pre-ART'for'any'reason,'including'
death.(
(
Figure(1(–(Stages(of(pre9ART(HIV(care((
Source:''Rosen'S,'Fox'MP'(2011)'Retention'in'HIV'Care'between'Testing'and'Treatment'in'Sub-Saharan'Africa:'A'Systematic'
Review.'PLoS'Med'8(7):'e1001056.'doi:10.1371/journal.pmed.1001056.'''
Panel(2—Stages(of(pre9ART(care(
STAGE' DESCRIPTION'
Stage(1((
(
Period'from'testing'HIV-positive'until'the'completion'of'initial'ART'eligibility'assessment.'
In'this'stage,'patients'who'test'positive'must'present'to'an'HIV'treatment'clinic'(often'
through'referral'from'a'separate'testing'site)'and'complete'their'first'assessment'for'ART'
eligibility.'The'stage'ends'when'the'patient'is'aware'of'their'ART'eligibility'status'and'
knows'what'the'next'step'is'(i.e.'pre-ART'care'or'ART'initiation).''
Stage(2((
(
Period'from'completing'the'first'ART'eligibility'assessment'to'ART'eligibility'for'those'not'
eligible'for'ART'at'the'time'of'testing'HIV-positive.'In'this'stage,'patients'must'remain'
actively'engaged'in'care,'as'indicated'by'returning'for'scheduled'ART'eligibility'
assessments'until'eligible'for'ART.'The'stage'ends'when'the'patient'is'aware'they'have'
become'ART'eligible.''
Stage(3(
(
Period'from'ART'eligibility'to'ART'initiation.'In'this'stage,'a'patient'must'complete'any'
treatment'readiness'steps'required'by'the'site'(e.g.'adherence'counseling)'and'then'
begin'treatment.'The'stage'ends'when'the'patient'has'been'prescribed'a'first'dose'of'
ARVs.'
(
Stage(1(–(HIV(testing(to(completion(of(ART(eligibility(assessment(
(
Stage'1'covers'the'period'from'the'time'a'patient'receives'a'positive'HIV'diagnosis'until'they'complete'
their'first'ART'eligibility'assessment.'Although'this'appears'to'be'a'relatively'straightforward'stage,'
published'studies'report'a'range'of'outcomes'and'time'intervals.''For'example,'one'study'from'
Mozambique'reported'the'proportion'of'patients'who'gave'a'blood'sample'and'returned'for'CD4'count'
results'within'60'days'(44%),14'while'another'study'from'Malawi'reported'only'the'proportion'of'
patients'who'returned'for'CD4'count'results'within'1'month'of'providing'the'blood'sample,'from'among'
those'who'gave'blood'samples'(55%).15'While'each'of'these'results'is'useful'to'the'program'to'which'it'
pertains,'it'is'difficult'to'compare'them'to'one'another'and'draw'any'conclusions'about'the'relative'
successes'of'the'programs.'
'
Stage'1'is'perhaps'the'most'difficult'to'monitor'with'routine'data'collection'systems,'as'HIV'testing'is'
often'provided'outside'clinical'facilities'(e.g.'during'testing'campaigns'or'at'stand-alone'HIV'testing'
facilities).'Patients'testing'HIV-positive'at'a'facility'that'does'not'provide'care'are'typically'referred'to'a'
clinic'for'pre-ART'care.'Even'when'testing'occurs'at'a'clinic,'testing'clients'are'often'not'assigned'an'
identification'number'that'allows'them'to'be'tracked'from'testing'to'clinical'care.''Estimating'retention'
in'Stage'1'requires'knowing'both'the'number'of'patients'who'test'positive'for'HIV'(denominator)'and'
the'number'of'those'who'reach'a'referral'clinic'and'complete'their'first'assessment'for'ART'eligibility'
(i.e.'provide'a'blood'sample'for'a'CD4'count'and'return'for'the'results).'Since'patients'testing'positive'at'
stand-alone'HIV'testing'facility'may'be'referred'to'multiple'clinics'for'pre-ART'care,'accurate'cohort'
reporting'requires'a'means'to'track'patients'from'testing'to'multiple'potential'referral'sites.''The'other'
challenge'in'reporting'on'Stage'1'is'determining'how'much'time'should'be'allowed'between'HIV'testing'
and'completion'of'ART'eligibility'assessment.'While'ideally'this'should'happen'as'quickly'as'possible,'
allowances'have'to'be'made'for'patient'delays'related'to'coping'with'an'HIV'diagnosis'and'the'logistics'
of'completing'a'referral,'as'well'for'as'provider'delays'related'to'determining'ART'eligibility.'
'
To'standardize'reporting,'for'Stage'1'we'define'retention'as'the'proportion'of'patients'who'test'HIV-
positive'during'a'specific'time'period'(e.g.,'2011'or'the'first'quarter'of'2011)'who'complete'an'initial'ART'
eligibility'assessment'within'3'and'12'months'of'HIV'testing.'We'recommend'reporting'cohort'outcomes'
at'3'months,'then'at'1'year.'For'Stage'1,'the'definition'we'propose'is'thus:'
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'
In'settings'in'which'populations'are'mobile'or'there'are'multiple'HIV'clinics'available,'we'recommend'
explicitly'excluding'from'the'denominator'patients'who'indicate'that'they'plan'to'have'an'ART'eligibility'
assessment'at'a'site'other'than'the'one'where'the'outcome'(numerator)'is'measured.'''
'
Because'data'for'Stage'1'may'be'generated'in'different'locations'(e.g.'an'HIV'testing'site'and'one'or'
more'referral'sites),'a'common,'unique'patient'identifier'used'across'sites'is'the'best'way'to'generate'
accurate'estimates'of'retention'in'this'stage.'The'identifier'could'be'a'national'ID'number'or'a'common'
patient'number'used'across'sites,'so'long'as'all'sites'collect'the'information.''Alternatively'if'the'
standard'practice'is'for'HIV'testing'sites'to'issue'referral'letters'to'patients,'which'patients'then'turn'in'
when'they'visit'the'referral'site,'it'may'be'possible'to'collect'and'match'referral'letters'received'with'the'
testing'site’s'log'of'letters'issued.'Essential'information'required'for'reporting'on'retention'in'Stage'1'
(and'each'stage)'is'shown'in'Panel'3'and'an'example'of'how'to'calculate'retention'in'Stage'1'is'shown'in'
Box'1.'
'
Panel(3(–(Review(of(reported(start(points,(outcomes(and(time(to(outcomes(reported(in(the(literature(and(
proposed(definitions(for(pre9ART(HIV(care(
Stage(1' Reported(in(literature' Proposed'
Start'point' HIV'test;'providing'sample'for'
CD4'count;'enrolling'in'care'
First'positive'HIV'test'
Outcomes'reported' Providing'sample'for'CD4'
count;'receiving'results'of'CD4'
count'
First'ART'eligibility'assessment'(patient'receives'
results'of'CD4'count'or'clinical'evaluation'and'is'
referred'to'pre-ART'care'or'ART)'
Time'to'achieving'
outcome'
7-183'days;'1/3'did'not'report'
interval'
3'months'and'1'year'after'HIV'test'
Data'required'for'each'
patient'in'cohort'
n/a' Date'of'HIV'test,'date'of'a'blood'draw'for'CD4'
count'(where'done),'date'of'return'to'receive'CD4'
count'results'or'have'clinical'assessment'for'ART'
eligibility''
Stage(2( Reported(in(literature( Proposed(
Start'point' Staging;'referral'from'HIV'test;'
enrollment'in'care'
Referral'to'pre-ART'care'after'staging'
Outcomes'reported' Various'one-time'and'repeat'
events'(enrollment'in'care;'
linked'to'or'attending'care;'
repeat'CD4'count'by'date'of'
data'censoring'or'within'1'year)'
Learning'eligibility'status'within'6'months'of'all'
scheduled'visit'according'to'the'site'protocol;'or'
completed'at'least'1'ART'eligibility'assessment'
within'one'year'since'the'date'being'reported'to'
Time'to'achieving'
outcome'
122-1826'days;'1/3'did'not'
report'interval'
12-months,'then'12'monthly'intervals'
Data'required'for'each'
patient'in'cohort'
n/a' Date'of'completing'first'ART'eligibility'assessment,'
date'of'all'scheduled'ART'eligibility'assessments'
within'the'reporting'period'and'the'date'of'
attending'all'ART'eligibility'visits'within'the'
reporting'period'
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Stage(3' Reported(in(literature' Proposed'
Start'point' Treatment'eligibility;'first'clinic'
visit;'HIV'test'
Patient'learns'of'treatment'eligibility'
Outcomes'reported' ART'initiation'by'date'of'data'
censoring;'proportion'not'
initiated'
ART'initiation'within'3'months'of'learning'
eligibility'
Time'to'achieving'
outcome'
90-1096'days;'1/2'did'not'
report'interval'
3'months,'then'3-monthly'intervals'
Data'required'for'each'
patient'in'cohort'
n/a' Date'first'becoming'ART'eligible,'date'of'
completion'of'all'ART'readiness'steps,'date'of'ART'
initiation'
'
Box(1(9(Example(of(Retention(calculation(in(Stage(1(
Description( Calculation( Example(
Time'period'for'cohort'enrollment'(HIV'test)' ' January'1-December'31,'2009'
Earliest'date'at'which'a'3'month'cohort'retention'evaluation'can'be'
completed'(at'least'3'months'after'last'patient'enrolled)'
' April'1,'2010'
#'of'patients'testing'HIV-positive'during'period'(a)' ' 1,000'
#'of'patents'transferring'out'(requesting'referral'to'external'site)'(b)' ' 100'
#'of'patients'in'cohort'for'evaluation'at'3'months'(c)' a-b' 900'
#'of'eligible'patients'completing'1st'eligibility'assessment'within'3'
months'of'HIV'testing'(d)'
'
450'
Retention'in'Stage'1'at'three'months' d/c' 50%'
As'an'example'of'how'to'calculate'retention'in'Stage'1,'suppose'4,000'patients'tested'for'HIV'in'2009'at'a'clinic'providing'both'
testing'and'care'and'treatment'services.''Among'these'4,000,'1,000'tested'positive'for'HIV'(20%'prevalence).''For'this'cohort'of'
1,000'patients,'the'program'would'need'to'wait'until'April'2010'to'review'records'to'determine'what'proportion'completed'an'
ART'eligibility'assessment'within'3'months'of'the'HIV'test.''In'this'example,'of'the'1,000'patients'testing'HIV'positive'in'2009,'
100'requested'referral'to'another'site'for'further'HIV'care'and'treatment'and'were'therefore'excluded'from'the'denominator.''
Among'the'900'not'referred'elsewhere,'450'completed'their'first'ART'eligibility'assessment'within'3'months'of'HIV'testing.''
Retention'in'Stage'1'at'three'months'was'thus'0.50.'
'
Stage(2(–(Completing(Staging(to(ART(eligibility('
!
Stage'2'covers'the'period'from'completion'of'the'first'ART'eligibility'assessment'until'ART'eligibility'is'
established.'Patients'who'end'Stage'1'already'eligible'for'ART'move'directly'to'Stage'3.''Defining'
retention'in'Stage'2'is'more'difficult'than'in'Stages'1'and'3'because'the'time'spent'in'Stage'2'and'the'
steps'required'within'the'stage'vary,'depending'on'each'individual’s'disease'stage'at'HIV'diagnosis'and'
the'pace'of'disease'progression'after'that.'Unlike'Stages'1'and'3,'successful'retention'in'Stage'2'may'
involve'repeating'the'same'step'(monitoring'visit)'multiple'times,'rather'than'moving'from'a'start'point'
to'an'end'point'just'once.'Moreover,'HIV'care'programs'differ'widely'in'their'protocols'for'patient'
management'in'Stage'2,'particularly'in'terms'of'the'recommended'time'intervals'between'monitoring'
visits.''A'universally'applicable'time'period'for'recognizing'loss'to'care'is'thus'difficult'to'define.''While'a'
program'that'requires'pre-ART'care'visits'every'three'months,'for'example,'might'consider'a'patient'
who'does'not'return'for'six'months'to'be'lost'to'care,'in'a'program'that'schedules'visits'only'every'six'
months'no'patients'could'be'lost'to'care'in'the'first'six'months.''The'literature'reflects,'and'often'
amplifies,'this'variability.''One'study'in'South'Africa'used'the'proportion'of'patients'who'had'a'repeat'
CD4'count'for'ART'eligibility'assessment'within'13'months'of'the'first'ART'eligibility'assessment'(45%)'to'
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indicate'retention'in'pre-ART'care,'for'example,16'while'another'study'in'Ethiopia'reported'the'
proportion'of'patients'initiating'care'or'still'in'care'at'date'of'data'censoring'(70%).17'The'use'of'
different'endpoints'by'these'studies'complicates'what'was'already'a'difficult'comparison'since'the'
protocols'for'visits'in'pre-ART'care'may'have'been'different'between'the'study'sites.''Accordingly,'the'
interpretation'of'retention'measures'for'this'stage'of'care'will'always'need'to'be'made'in'light'of'the'
characteristics'of'the'specific'care'program'in'question.'
'
In'Stage'2'patients'can'have'multiple'ART'eligibility'assessments'over'time.'To'deal'with'the'variability'in'
visit'schedules'and'the'need'for'an'indicator'of'engagement'in'care,'we'define'two'ways'a'patient'can'
be'considered'retained'in'care'over'time.'Retention'in'Stage'2'is'the'proportion'of'patients'who'have'
completed'an'initial'ART'eligibility'assessment'who'either:'a)'complete'all'scheduled'ART'eligibility're-
assessments'within'six'months'of'the'site’s'standard'visit'schedule;'or'b)'had'an'assessment'within'the'
past'year'of'the'assessment'period'(e.g.'12,'24'months,'etc.)'and'were'not'ART'eligible'at'that'
assessment.''The'first'indicator'of'“engagement'in'care”'(completing'all'visits'on'schedule'within'6'
months)'allows'a'patient'to'be'successful'if'they'attend'all'scheduled'visits,'even'if'they'eventually'reach'
eligibility'at'a'low'CD4'count.'The'second'indicator'(completing'at'least'one'eligibility'assessment'within'
the'12'months'of'the'assessment'period'at'which'the'patient'was'not'ART'eligible)'allows'a'patient'to'
also'be'successful'even'if'they'miss'some'visits,'as'long'as'they'have'completed'a'visit'within'the'year'
and'remain'above'the'ART'eligibility'threshold'when'reassessed.''
'
Retention'for'Stage'2'is'then'defined'as:'
The'data'required'to'report'on'Stage'2'are'simpler'to'collect'than'for'Stage'1'as'they'can'typically'all'be'
obtained'from'one'site,'but'a'longer'duration'of'follow'up'is'needed.'The'HIV'care'site’s'data'system'
must'use'a'unique'patient'identifier'and'record'the'date'of'all'ART'eligibility'assessments'done.'See'Box'
2'for'an'example'of'how'to'calculate'retention'in'Stage'2.'
'
Box(2(9(Example(of(retention(calculation(in(Stage(2,(for(a(pre9ART(program(with(69monthly(follow9up(visits(
Description( Calculation( Example(
Time'period'for'cohort'enrollment'(completed'1st'ART'eligibility'
assessment'and'not'eligible'for'ART'at'that'assessment)'
' January'1-December'31,'2008'
Earliest'date'by'which'all'patients'should'have'completed'first'six-
month'follow'up'visit'
' July'1,'2009'
Earliest'date'at'which'a'12-month'cohort'evaluation'can'be'
completed'
' January'1,'2010'
#'patients'enrolled'in'cohort'(a)' ' 1,000'
#'transferred'out'during'the'12'months'after'entering'cohort'(b)' ' 50'
#'of'patients'remaining'in'cohort'for'12'month'assessment'(c)' a-b' 950'
#'of'patients'completing'all'scheduled'monitoring'visits'within'6'
months'of'schedule'(d)'
' 200'
#'of'patients'who'did'not'complete'all'scheduled'monitoring'visits'
within'6'months'of'schedule'but'whose'last'ART'eligibility'
assessment'within'12'months'was'above'eligibility'threshold'(e)'
'
100'
Total'retained'at'12'months'(f)' d+e' 300'
Retention'in'Stage'2'at'12'months' f/c' 31.5%'
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As'an'example'of'how'to'calculate'retention'in'Stage'2,'suppose'2,000'patients'completed'their'first'ART'eligibility'assessment'
at'the'treatment'site'in'2008.''Among'these,'1,000'were'eligible'for'ART'and'1,000'were'not.''Among'the'1000'not'eligible,'all'
patients'are'scheduled'to'return'to'the'site'after'6'months'for'a'follow'up'medical'exam'and'ART'eligibility'assessment.'Thus,'all'
patients'could'have'a'12'month'follow'on'Jan'1,'2010.''If'50'subjects'transferred'out'of'care'over'the'12'months'then'950'
subjects'would'be'eligible'for'assessment.'Suppose'200'patients'completed'all'scheduled'monitoring'visits'within'6'months'of'
the'schedule'and'a'further'100'patients'didn’t'complete'al'all'scheduled'monitoring'visits'within'6'months'of'schedule'but'had'
their'last'ART'eligibility'assessment'within'12'months'and'were'not'yet'eligible'for'ART'at'that'time.'Retention'in'Stage'2'at'12'
moths'would'be'300/950'='0.315.'''
'
Stage(3(–ART(eligibility(to(ART(initiation(
'
Stage'3'covers'the'period'from'first'establishing'ART'eligibility'until'ART'initiation.'Retention'in'Stage'3'is'
the'easiest'of'the'three'stages'to'define'and'measure'as'it'has'a'consistent'start'point'(determination'of'
ART'eligibility)'and'end'point'(ART'initiation)'and'because'retention'can'be'defined'in'terms'of'time'
since'ART'eligibility'was'established'rather'than'in'relation'to'the'most'recent'visit.'Stage'3'starts'with'
the'patient'learning'of'his'or'her'eligibility,'rather'than'with'the'exact'point'of'biological'eligibility,'
because'the'latter'cannot'be'determined'in'routine'care.'
'
The'main'challenge'in'defining'retention'in'Stage'3'arises'from'programmatic'variation'in'what'is'
required'of'a'patient'between'eligibility'and'initiation.''Programs'typically'require'anywhere'from'one'to'
four'clinic'visits'for'various'“treatment'readiness”'activities,'like'adherence'counseling.'The'schedule'of'
required'visits'varies'among'countries'and'between'programs'and'sites'within'countries.''It'may'even'
vary'within'sites,'as'patients'with'very'low'CD4'counts'are'sometimes'“fast-tracked”'and'allowed'to'
start'ART'without'the'usual'readiness'activities.'
'
In'our'review,'we'found'that'most'reports'used'the'same'start'and'end'points'(ART'eligibility'to'ART'
assessment),'but'there'was'enough'variability'in'definitions'and'time'intervals'to'make'synthesis'
difficult.'One'report'from'Mozambique,'for'example,'reported'the'proportion'initiating'ART'within'90'
days'of'eligibility'(31%),14'while'another'from'South'Africa'reported'the'proportion'of'patients'who'
initiated'treatment'within'3'months'of'the'patient’s'last'required'pre-ART'visit'(83%)9'and'a'third,'from'
Malawi,'reported'the'proportion'initiating'ART'by'the'date'of'data'censoring'(64%).15'These'three'
outcomes'cannot'be'compared,'even'though'their'end'point'is'the'same.'
'
For'Stage'3,'we'define'retention'as'the'proportion'of'ART'eligible'patients'who'initiate'ART'(i.e.'ARVs'are'
dispensed)'within'three'months'of'learning'of'their'ART'eligibility:''
' '
While'this'definition'aims'to'be'applicable'and'relevant'to'as'wide'a'range'of'programs'as'possible,'it'
does'not'directly'address'the'goal'of'raising'average'CD4'counts'at'ART'initiation.'For'this'purpose,'the'
definition'could'be'modified'to'report'the'proportion'of'patients'initiating'ART'above'a'CD4'count'floor'
that'is'specific'to'the'program'in'question.'For'example,'in'programs'that'have'recently'raised'the'
threshold'for'initiating'ART'from'a'CD4'count'<200'to'a'CD4'count'<'350,'reporting'the'proportion'of'
patients'who'initiate'treatment'at'CD4'counts'between'200'and'350,'or'even'above'100,'may'be'useful.'
'
Retention'in'Stage'3'should'be'reported'for'a'cohort'at'3'months'after'ART'eligibility'and'3'monthly'
intervals'thereafter.'An'example'of'how'to'calculate'retention'in'Stage'3'is'shown'in'Box'3.'
(
(
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Box(3(9(Example(of(retention(calculation(in(Stage(3(
Description( Calculation( Example(
Time'period'for'cohort'enrollment'(ART'eligibility'established)' ' January'1-December'31,'2009'
Earliest'date'at'which'3-month'cohort'retention'evaluation'can'be'
completed'
' April'1,'2010'
#'of'patients'who'became'ART'eligible'during'period'(a)' ' 500'
#'of'patents'transferring'out'within'3'months'of'becoming'ART'
eligible'(b)'
' 25'
#'of'patients'in'cohort'for'evaluation'at'3'months'(c)' a-b' 475'
#'of'eligible'patients'initiating'ART'within'3'months'of'HIV'testing'
(d)'
' 200'
Retention'in'Stage'3'at'three'months' d/c' 42%'
As'an'example'of'how'to'calculate'retention'in'Stage'3,'suppose'500'patients'became'ART'eligible'between'January'and'
December'2009.''A'program'would'need'to'wait'until'April'2010'to'review'records'to'determine'who'completed'initiated'ART.'If'
in'April'2011,'of'the'500'patients'becoming'ART'eligible'during'2009,'25'transferred'to'another'site.'Among'the'475'not'
referred'elsewhere,'200'initiated'ART'within'3'months'of'HIV'testing.''In'this'case,'retention'in'Stage'3'at'three'months'is'0.42.'''
'
Conclusions(
(
New'guidelines'and'objectives'for'HIV'care'and'treatment'programs,'in'resource-rich'as'well'as'
resource-limited'countries,'call'for'large-scale'HIV'testing'aimed'at'early'diagnosis'of'HIV'infection'and'
large-scale'ART'provision,'with'thresholds'that'allow'much'earlier'treatment'initiation'than'in'the'past.1,'
18''For'these'goals'to'be'met,'patients'diagnosed'with'HIV'must'be'enrolled'and'retained'in'pre-ART'
care.'Consistent'terminology'for'studying'pre-ART'care'will'facilitate'the'collection'of'relevant'data,'
improve'measuring'and'reporting'of'outcomes,'and'enhance'comparability'of'results'across'programs'
and'countries.'''
'
The'definitions'we'propose'offer'a'strategy'for'improving'the'consistency'and'comparability'of'data'
collected'in'observational'and'intervention'studies.(We'defined'pre-ART'retention'in'terms'of'
completing'the'stages'of'pre-ART'care'within'a'reasonable'time'frame'or,'for'Stage'2,'engagement'in'
care'over'time.''We'aimed'to'make'our'definitions'and'reporting'time'frames'practical'within'existing,'
routine'reporting'systems'and'reasonable'with'respect'to'the'amount'of'data'needed,'based'on'the'
published'literature'and'our'own'experience.'Future'empirical'analyses'of'program'data'sets'may'allow'
our'definitions'to'be'further'refined'by'determining'the'time'intervals'that'best'predict'permanent'loss'
from'pre-ART'care,'as'has'been'done'recently'with'post-ART'loss'to'care.19'
'
It'is'important'to'note'that'the'definitions'we'propose'are'intended'for'evaluation'of'cohorts,'not'for'
managing'individual'patients'or'for'quality'improvement'of'specific'programs.'A'clinician'may'not'regard'
completion'of'scheduled'visits'in'Stage'2'within'six'months'of'the'program'schedule'to'be'a'strict'
enough'criterion'for'measuring'the'success'of'any'individual'patient.'Similarly,'some'pre-ART'programs'
may'not'be'satisfied'with'adherence'to'a'visit'schedule'as'a'measure'of'retention,'but'instead'focus'on'
assessing'the'proportion'of'patients'without'serious'morbidity.''It'is'unlikely'that'any'single'set'of'
definitions'can'meet'the'needs'of'everyone'with'an'interest'in'pre-ART'care,'and'ours'are'aimed'at'one'
particular'audience.''
'
One'of'the'purposes'of'defining'terms'is'to'deliberately'restrict'what'is'included'and'excluded.'Our'
definitions'deliberately'exclude'two'important'categories'of'information.'First,'there'are'many'reasons'
why'patients'are'lost'from'pre-ART'care.'For'some,'lack'of'current'illness'may'be'the'main'driver,'while'
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for'others'stigma'or'lost'income'due'to'long'clinic'queues'may'be'greater'concerns.'The'definitions'we'
have'proposed'are'designed'to'allow'for'consistent'reporting'but'do'not'attempt'to'distinguish'among'
reasons'for'loss'to'care.'Second,'we'deliberately'defined'pre-ART'care'to'begin'after'a'patient'tests'
positive'for'HIV'infection.'If'a'large'portion'of'patients'only'test'for'HIV'when'they'are'already'seriously'
ill'and'treatment'eligible,'thereby'bypassing'Stage'2'entirely,'pre-ART'care'programs'will'fail'to'prevent'a'
large'share'of'HIV-related'morbidity'and'mortality,'and'average'starting'treatment'CD4'counts'will'
remain'low.''In'studies'included'in'our'review'for'which'the'proportion'of'patients'eligible'for'treatment'
at'HIV'testing'or'enrollment'in'pre-ART'care'could'be'determined,'nearly'half'were'already'eligible'for'
ART'(median'[IQR]'49%'[34-53%]).'Improving'pre-ART'care'will'have'no'impact'on'patients'who'were'
already'late'presenters'for'treatment'when'first'diagnosed'with'HIV.''
'
We'believe'that'more'and'better'reporting'on'retention'in'pre-ART'care'is'essential'to'improve'the'
allocation'of'limited'resources'and'achieve'targets'for'HIV'treatment.''To'do'this,'clear'definitions'of'
terms,'as'well'as'better'data'collection'systems,'are'essential.''By'using'the'standardized'definitions'
proposed'here,'we'and'other'researchers'will'be'able'to'provide'better'information'and'guidance'to'
policy'makers'on'the'extent'of'pre-ART'retention'and'loss'to'care,'track'changes'over'time,'and'develop'
and'test'interventions'to'improve'pre-ART'programs.'
'
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